Fact Sheet 1 - Expanded and Accelerated Price Disclosure Cycles

 

Main Disclosure Cycles

The first Main Disclosure Cycle commences on 1 December 2010 and will include all brands of non-exempt pharmaceutical items containing drugs on the F2 Formulary not already subject to Price Disclosure arrangements. The data collection period will be 10 months.

All subsequent Main Disclosure Cycles will commence on 1 October immediately following completion of data collection for the prior cycle. A cycle includes the period up to its relevant reduction day.

Data collection period

The data collection period for the Main Disclosure Cycle ends on 30 September in the year after the year in which the brand became subject to Expanded and Accelerated Price Disclosure (EAPD).

Reporting periods

The first Main Disclosure Cycle will have the following reporting periods:

Main cycle no.	Reporting period	Start date	End date	Submission Deadlines	Scheduled reduction day
1	1	1 December 2010	31 March 2011	12 May 2011	1 April 2011
	2	1 April 2012	30 September 2011	11 November 2011

The subsequent Main Disclosure Cycles will have the following reporting periods:

Main cycle no.	Reporting period	Start date	End date	Submission Deadlines	Scheduled reduction day
2	1	1 October 2011*	31 March 2012	12 May 2012	1 April 2013
	2	1 April 2012	30 September 2012	11 November 2012
3	1	1 October 2012*	31 March 2013	12 May 2013	1 April 2014
	2	1 April 2013	30 September 2013	11 November 2013
4	1	1 October 2013*	31 March 2014	12 May 2014	1 April 2015
	2	1 April 2014	30 September 2014	11 November 2014

* If a brand lists on 1 July, 1 August or 1 September and is subject to EAPD for the first time it will join the subsequent main cycle proceeding these dates. Data collection for this brand will commence the date it becomes subject to EAPD.

Interim Supplementary Disclosure Cycle

There is one Interim Supplementary Disclosure Cycle to allow new F2 drug listings occurring between 2 December 2010 and up to 1 June 2011 (inclusive), to have a disclosure cycle of at least eighteen months.

Data collection period

The data collection period for the Interim Supplementary Disclosure Cycle ends on 31 May 2012.

Subsequent years

All brands in the Interim Supplementary Disclosure Cycle will move to the next available data collection period in a Main Disclosure Cycle (i.e. commencing 1 June 2012, for the main cycle data collection period ending 30 September 2013).

Reporting periods

The Interim Supplementary Disclosure Cycle will have the following reporting periods:

Reporting period	Start date	End date	Submission Deadlines	Scheduled reduction day
1	1 January 2011 – 1 March 2011*	31 March 2011	12 May 2011	1 December 2012
2	1 April 2011 – 1 June 2011*	30 September 2011	11 November 2011
3	1 October 2011	31 March 2012	12 May 2012
4	1 April 2012	31 May 2012	11 July 2012

* Start date is the date on which the brand becomes subject to price disclosure (which can vary).

Supplementary Disclosure Cycle A

Supplementary Disclosure Cycle A allows new F2 drugs listing between 2 October and 1 February, where the drug and manner of administration or a new manner of administration first becomes subject to EAPD requirements, to have a disclosure cycle of at least eighteen months.

The brand will then merge into the next available data collection period in a Main Disclosure Cycle. The first reporting period in the main cycle will be 1 February - 31 March.

Data collection period

The data collection period for Supplementary Disclosure Cycle A ends on 31 January.

Subsequent years

Following its completion of Supplementary Disclosure Cycle A, the brand will merge into the next available Main Disclosure Cycle.

Reporting periods

Supplementary Disclosure Cycle A will have the following reporting periods:

Reporting period	Start date	End date	Submission Deadlines	Scheduled reduction day
1	1 November – 1 February	31 March	12 May	1 August
2	1 April	30 September	11 November
3	1 October	31 January	14 March

* Start date is the date on which the brand becomes subject to price disclosure (which can vary)

Supplementary Disclosure Cycle B

Supplementary Disclosure Cycle B allows new F2 drugs listing between 2 February and 1 June, where the drug and manner of administration or a new manner of administration first becomes subject to EAPD requirements, to have a disclosure cycle of at least eighteen months.

The brand would then merge into the next available data collection period in a Main Disclosure Cycle. The first reporting period in the main cycle will be 1 June - 30 September

Data collection period

The data collection period for Supplementary Disclosure Cycle B ends on 31 May in the year after the year in which the brand became subject to EAPD.

Subsequent years

Following its completion of Supplementary Disclosure Cycle B, the brand will merge into the next available Main Disclosure Cycle.

Reporting periods

Supplementary Disclosure Cycle B will have the following reporting periods:

Reporting period	Start date	End date	Submission Deadlines	Scheduled reduction day
1	1 March*	31 March	12 May	1 December
2	1 April – 1 June*	30 September	11 November
3	1 October	31 March	12 May
4	1 April	31 May	11 July

* Start date is the date on which the brand becomes subject to price disclosure (which can vary).

NOTE: All Expanded and Accelerated Price Disclosure data must be submitted within 6 weeks of the end of each reporting period no matter which cycle a brand of drug is allocated.